ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon Print
COVID vaccines

Japanese drugmakers race to release COVID vaccines

KM Biologics and Daiichi Sankyo follow Shionogi in inoculation drive

Japanese vaccine makers are rushing to conduct Phase 2/3 trials of vaccines, aiming to put them in the market next year. (Nikkei photo)

TOKYO -- Japanese vaccine makers are racing to release COVID vaccines next year as they anticipate new virus variants and further outbreaks.

KM Biologics, a Meiji Holdings subsidiary, said on Wednesday that it is aiming for the release of its inactivated vaccine for use as booster shots next year. The Kumamoto-based company began a Phase 2/3 trial last week.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

Discover the all new Nikkei Asia app

  • Take your reading anywhere with offline reading functions
  • Never miss a story with breaking news alerts
  • Customize your reading experience

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more